Low levels of return on investment in R&D is an issue that has been bubbling beneath the surface of pharmaceutical companies for some time and the situation is coming to a head, threatening the industry’s future

Patient recruitment and retention remain the biggest challenges in clinical studies, it is surely time for industry to trial a new approach.

Learn about the origins of the medical affairs function, how far it’s come and where it may be heading in the future as key proprietor of patient centricity.

Isabelle Bocher-Pianka, Chief Patient Affairs Officer, Global Medical Affairs, Ipsen shares her thoughts on pharma’s mission to help improve patient lives, challenges that hinder patient centricity and seeking knowledge across industries.

The internet is a jungle, tangled and overgrown, dense with information overload. Among the unkempt chaos lies social media: a treasure trove of possibilities for the pharmaceutical industry.

Astronauts experience physical stress while in space and have a rigorous training programme prior, during, and after their expedition…

Survival rates for those with later-stage cancer are progressively increasing with better treatment and earlier diagnosis…

Psoriasis and AD are chronic, systemic inflammatory diseases of the skin characterised by upregulation of proinflammatory cytokines…

Acne is the most common skin condition in the USA, affecting over half of its population.1 It is an inflammatory skin disease that predominantly…